ArticleFrontiers in cardiovascular medicine2025
Temporal relationship between inflammation and metabolic disorders and its influence on atherosclerotic cardiovascular disease.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerotic cardiovascular disease (ASCVD) is one of the conditions driven by imbalances in inflammatory and metabolic regulation. Although the temporal and causal relationships between inflammation and metabolic disorders are complex, the sequence in which they occur remains unclear. This study aimed to explore the temporal relationship between inflammation [high-sensitivity C-reactive protein (hsCRP)) and metabolic disorders (Continuous Metabolic syndrome score (cMets)] and their cumulative joint effects on ASCVD. Methods: This prospective cohort study was conducted in two parts. First, a longitudinal analysis was performed on 62,296 participants over a 4.05-year follow-up period using a cross-lagged panel model to investigate the directional relationship between hsCRP and cMetS. Second, after excluding 3,619 participants with a history of ASCVD, the remaining individuals were categorized into four groups to examine the time-weighted cumulative joint exposure of hsCRP and cMetS on the risk of ASCVD and its subtypes using Cox proportional hazards models. Results: There was a bidirectional relationship between hsCRP and cMetS, The robustness of the pathway from baseline hsCRP to follow-up cMetS ( Conclusion: There is a bidirectional relationship between inflammation and metabolic disorders, with inflammation appearing to precede metabolic disorders. Concurrent exposure to both inflammation and metabolic disorders significantly increases the risk of ASCVD, particularly among individuals under 60 years of age and those classified as having a low risk of developing ASCVD in the next 10 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.